167 related articles for article (PubMed ID: 3922776)
21. Multiple receptors for brain dopamine in behavior regulation: concept of dopamine-E and dopamine-I receptors.
Cools AR; van Rossum JM
Life Sci; 1980 Oct; 27(14):1237-53. PubMed ID: 6255271
[No Abstract] [Full Text] [Related]
22. Presynaptic effects of 2-aminotetralins on striatal dopaminergic neurons.
Hoffmann IS; Naylor RJ; Cubeddu LX
J Pharmacol Exp Ther; 1980 Nov; 215(2):486-93. PubMed ID: 7441511
[TBL] [Abstract][Full Text] [Related]
23. Radioreceptor binding reveals the potencies of N,N-disubstituted 2-aminotetralins as D2 dopamine agonists.
Beart PM; Cook CJ; Cincotta M; de Vries DJ; Tepper P; Dijkstra D; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):487-93. PubMed ID: 2963964
[TBL] [Abstract][Full Text] [Related]
24. Is TL-99 a selective presynaptic dopamine receptor agonist?
Horn AS; De Vries J; Dijkstra D; Mulder AH
Eur J Pharmacol; 1982 Sep; 83(1-2):35-45. PubMed ID: 7128699
[TBL] [Abstract][Full Text] [Related]
25. A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity.
Feenstra MG; Sumners C; Goedemoed JH; de Vries JB; Rollema H; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(2):108-15. PubMed ID: 6646238
[TBL] [Abstract][Full Text] [Related]
26. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins.
Weinstock J; Gaitanopoulos DE; Oh HJ; Pfeiffer FR; Karash CB; Venslavsky JW; Sarau HM; Flaim KE; Hieble JP; Kaiser C
J Med Chem; 1986 Sep; 29(9):1615-27. PubMed ID: 2875183
[TBL] [Abstract][Full Text] [Related]
28. (+)-UH 232 and (+)-UH 242: novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors.
Svensson K; Hjorth S; Clark D; Carlsson A; Wikström H; Andersson B; Sanchez D; Johansson AM; Arvidsson LE; Hacksell U
J Neural Transm; 1986; 65(1):1-27. PubMed ID: 3083041
[TBL] [Abstract][Full Text] [Related]
29. A homologous series of N-alkylated cis-(+)-(1 S, 2 R)-5-methoxy-1-methyl-2-aminotetralins: central dopamine receptor antagonists showing profiles ranging from classical antagonism to selectivity for autoreceptors.
Svensson K; Carlsson A; Johansson AM; Arvidsson LE; Nilsson JL
J Neural Transm; 1986; 65(1):29-38. PubMed ID: 3958706
[TBL] [Abstract][Full Text] [Related]
30. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
31. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
[TBL] [Abstract][Full Text] [Related]
32. Enantiomers of monohydroxy-2-aminotetralin derivatives and their activity at dopamine autoreceptors as studied by brain dialysis.
Timmerman W; Tepper PG; Dijkstra D; Stoelwinder H; Grol CJ; Westerink BH; Horn AS
Eur J Pharmacol; 1991 Jun; 199(2):145-51. PubMed ID: 1683287
[TBL] [Abstract][Full Text] [Related]
33. N-n-propyl-norapomorphine: an extremely potent stimulant of dopamine autoreceptors.
Argiolas A; Mereu G; Serra G; Melis MR; Fadda F; Gessa GL
Brain Res; 1982 Jan; 231(1):109-16. PubMed ID: 6799148
[TBL] [Abstract][Full Text] [Related]
34. The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo.
van Oene JC; de Vries JB; Horn AS
Naunyn Schmiedebergs Arch Pharmacol; 1984 Oct; 327(4):304-11. PubMed ID: 6514014
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of rat brain monoamine oxidase type A by 2-aminotetralin and tetrahydroisoquinoline analogues of dopamine.
Feenstra MG; van der Velden T; Dijkstra D; Hommes OR; Horn AS
Pharm Weekbl Sci; 1983 Aug; 5(4):131-3. PubMed ID: 6622205
[TBL] [Abstract][Full Text] [Related]
36. trans-N-n-Propyl-7-hydroxy-octahydrobenzo(f)quinoline, a rigid 3-PPP analogue with greater potency but lack of selectivity for dopamine autoreceptors.
Van Oene JC; Houwing HA; Dijkstra D; Horn AS
Eur J Pharmacol; 1983 Mar; 87(4):491-5. PubMed ID: 6406238
[TBL] [Abstract][Full Text] [Related]
37. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
38. Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
Grol CJ; Jansen LJ; Rollema H
J Med Chem; 1985 May; 28(5):679-83. PubMed ID: 4039369
[TBL] [Abstract][Full Text] [Related]
39. Interaction of the putative dopamine autoreceptor agonists 3-PPP and TL-99 with [3H]apomorphine binding sites in rat striatal membranes.
Williams M; Totaro JA
Eur J Pharmacol; 1982 Dec; 86(1):35-42. PubMed ID: 7160432
[TBL] [Abstract][Full Text] [Related]
40. N-Alkylated 2-aminotetralins: central dopamine-receptor stimulating activity.
Hacksell U; Svensson U; Nilsson JL; Hjorth S; Carlsson A; Wikström H; Lindenberg P; Sanchez D
J Med Chem; 1979 Dec; 22(12):1469-75. PubMed ID: 317109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
